<DOC>
	<DOCNO>NCT01088165</DOCNO>
	<brief_summary>Psoriasis vulgaris longer consider chronic inflammatory disease restrict skin . Evidence accumulate past psoriasis chronic inflammatory systemic disease . As rheumatoid arthritis , chronic inflammatory process play central role pathogenesis associate comorbidities diabetes cardiovascular disease . Since several year armamentarium psoriasis treatment broaden availability TNF alpha blocker . These neutralize systemic TNF alpha play central role pathogenesis psoriasis also link inflammatory pathway diabetes cardiovascular disease . While study investigate positive effect TNF alpha blocker associate cardiovascular disease rheumatoid arthritis patient , research data exist effect therapeutic agent patient moderate severe chronic plaque psoriasis . The present study aim determine effect adalimumab , potent frequently prescribe TNF alpha blocker treatment psoriasis , different diabetic cardiovascular risk factor patient receive treatment remedy moderate severe plaque type psoriasis . The study design explore whether adalimumab capable prevent modulate psoriasis-associated comorbidities block systemic inflammation . The effect adalimumab compare fumaric acid , represent establish traditional systemic treatment option moderate severe psoriasis . Study hypothesis : Therapy adalimumab lead improvement several parameter reflect risk diabetes cardiovascular disease patient chronic plaque psoriasis due chronic inflammation . Endothelial dysfunction , assess ultrasound flow mediate dilatation , serve primary outcome measure . Other risk factor blood lipid , hsCRP , IL-6 , endothelial adhesion molecule , parameter glucose metabolism carotid intima-media thickness secondary outcome . Aim : If adalimumab and/or fumaric acid show significant impact mention parameter , finding would offer new perspective long term management psoriatic patient comorbidities . Study design : Randomized , prospective , control , parallel group study Study population : 66 patient</brief_summary>
	<brief_title>The Influence Adalimumab Cardiovascular Metabolic Risk Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Chronic severe plaque type psoriasis ( PASI &lt; 10 ) require systemic treatment . Nonresponse contraindication previous systemic and/or light treatment PASI ≥ 10 , BSA ≥ 10 Age 18 80 year Women childbearing potential take contraceptive measure Pregnant breastfeed woman Patients history ongoing malignancy , chronic infection autoimmune disease Patients severe impairment general health Patients unable understand comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Fumaric acid ester</keyword>
</DOC>